DYANAVEL XR 10
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DYANAVEL XR 10 (DYANAVEL XR 10).
Dyanavel XR is a central nervous system stimulant that increases extracellular levels of dopamine and norepinephrine by inhibiting their reuptake and enhancing their release from presynaptic neurons.
| Metabolism | Metabolized primarily via deamination and oxidation to 4-hydroxyamphetamine and norephedrine. CYP2D6 involved in minor hydroxylation pathways. |
| Excretion | Renal (80-90% as unchanged drug); fecal (minor, 1-5%) |
| Half-life | 12 hours (amphetamine); clinical context: extended-release profile allows once-daily dosing |
| Protein binding | 20-25% (amphetamine); albumin, alpha1-acid glycoprotein |
| Volume of Distribution | 3.5-4.6 L/kg; indicates extensive tissue distribution |
| Bioavailability | 90-100% for extended-release oral formulation |
| Onset of Action | 30-60 minutes (extended-release oral); peak concentration at 5-6 hours |
| Duration of Action | 12 hours (clinical effect); designed for daytime dosing with once-daily administration |
| Molecular Weight | 215.72 |
Recommended starting dose for adults is 10 mg orally once daily in the morning. May increase in increments of 5-10 mg at weekly intervals based on tolerability and response. Maximum recommended dose is 60 mg/day.
| Dosage form | TABLET, EXTENDED RELEASE |
| Renal impairment | For GFR 15-30 mL/min: reduce dose by 50%. For GFR <15 mL/min: not recommended. Hemodialysis: supplemental dose not required; administer after dialysis if needed. |
| Liver impairment | Child-Pugh Class B: reduce dose by 50%. Child-Pugh Class C: not recommended. |
| Pediatric use | For patients aged 6-12 years: starting dose 5-10 mg orally once daily in the morning; may increase by 5 mg weekly. For patients aged 13-17 years: starting dose 10 mg orally once daily; may increase by 5-10 mg weekly. Maximum 60 mg/day. |
| Geriatric use | Elderly patients may be more sensitive to the effects; start at the low end of the dosing range (5 mg once daily) and titrate cautiously due to increased risk of adverse effects such as increased blood pressure, insomnia, and cardiovascular events. |
| 1st trimester | Amphetamines are teratogenic in animal studies; increased risk of congenital malformations, including cardiovascular and oral clefts, with first trimester exposure. Use only if benefit outweighs risk. |
| 2nd trimester | May cause fetal growth restriction, prematurity, and neonatal withdrawal. Use only if clearly needed. |
| 3rd trimester | Third trimester use associated with premature delivery, low birth weight, and neonatal withdrawal symptoms (e.g., dysphoria, agitation, excessive crying). |
Clinical note
Comprehensive clinical and safety monograph for DYANAVEL XR 10 (DYANAVEL XR 10).
| Placental transfer | Amphetamines cross the placenta readily, with fetal plasma concentrations approximately 50-100% of maternal concentrations. |
| Breastfeeding | Amphetamines are excreted into breast milk in small amounts but may accumulate in infants with impaired clearance. Irritability, poor sleeping pattern, and decreased weight gain have been reported. Monitor infant for agitation, insomnia, and feeding difficulties. Use lowest effective dose and consider alternative therapies if possible. |
■ FDA Black Box Warning
DYANAVEL XR has a high potential for abuse and misuse, which can lead to tolerance, physical dependence, and substance use disorder. Misuse may cause sudden death or serious cardiovascular events.
| Serious Effects |
Hypersensitivity to amphetamines or any component of the formulationConcurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days of MAOI therapy (hypertensive crisis risk)GlaucomaHyperthyroidismAgitated statesHistory of drug abuseSymptomatic cardiovascular disease (including moderate to severe hypertension, advanced arteriosclerosis, hyperthyroidism, tachyarrhythmias)
| Precautions | Serious cardiovascular events including sudden death in patients with structural cardiac abnormalities or other serious heart problems., Blood pressure and heart rate increases; monitor regularly., Psychiatric adverse events including exacerbation of pre-existing psychosis, manic episodes, and new psychotic or manic symptoms., Long-term suppression of growth in pediatric patients., Peripheral vasculopathy including Raynaud's phenomenon., Serotonin syndrome risk when co-administered with serotonergic drugs. |
| Food/Dietary |
Loading safety data…
| Lactation Rating | L4 - Possibly Hazardous |
| Teratogenic Risk | First trimester: Limited human data; animal studies show increased risk of cardiovascular and neural tube defects at high doses. Second/third trimester: Increased risk of preterm delivery, low birth weight, and neonatal withdrawal syndrome. Avoid in pregnancy unless benefit outweighs risk. |
| Fetal Monitoring | Monitor maternal blood pressure, heart rate, and weight; fetal growth and heart rate via ultrasound and nonstress tests if used during pregnancy. Assess for preterm labor. |
| Fertility Effects | May impair fertility in females via hormonal alterations; in males, may cause erectile dysfunction or reduced sperm motility. Reversible upon discontinuation. |
| Grapefruit and grapefruit juice may increase amphetamine levels and should be avoided. High-fat meals may delay absorption but do not significantly alter overall exposure. Acidic foods (e.g., citrus fruits, sodas) can decrease absorption; take consistently with regard to meals. Avoid caffeine or other stimulants. |
| Clinical Pearls | Dyanavel XR 10 is an extended-release amphetamine suspension. Do not substitute for other amphetamine products on a mg-per-mg basis due to different pharmacokinetic profiles. Avoid use in patients with known structural cardiac abnormalities or serious heart arrhythmias. Monitor for weight loss and growth suppression in pediatric patients. May cause blood pressure and heart rate increases; assess baseline cardiovascular status. |
| Patient Advice | Take exactly as prescribed; do not crush, chew, or divide the suspension. · Take once daily in the morning with or without food. · Swallow the suspension whole; do not mix with liquids or food. · Do not take in the afternoon or evening to avoid insomnia. · Store at room temperature; do not freeze. · Avoid alcohol while taking this medication. · Report any chest pain, shortness of breath, or fainting to your doctor immediately. · May cause dizziness or blurred vision; avoid driving until you know how it affects you. · Inform your doctor of all other medications, including MAOIs, anticoagulants, or antihypertensives. · Do not stop abruptly; taper under medical supervision to avoid withdrawal symptoms. |